Holen Sie sich die Stockscreener-App
57.61
3.19%
-1.90
Vorhandelsmarkt:
57.81
0.20
+0.35%
Schlusskurs vom Vortag:
$59.51
Offen:
$60
24-Stunden-Volumen:
402.58K
Relative Volume:
0.63
Marktkapitalisierung:
$1.68B
Einnahmen:
$232.39M
Nettoeinkommen (Verlust:
$-26.79M
KGV:
-53.32
EPS:
-1.0804
Netto-Cashflow:
$4.41M
1W Leistung:
+11.58%
1M Leistung:
-8.77%
6M Leistung:
+27.94%
1J Leistung:
+141.05%
1-Tages-Spanne:
$57.38
$60.49
1-Wochen-Bereich:
$50.92
$60.49
52-Wochen-Spanne:
$17.11
$73.30
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
57.61 | 1.73B | 232.39M | -26.79M | 4.41M | -1.0804 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
Daily Brief United States: SpaceX, Crude Oil, DPC Holdings, CRB Commodity Index, Vistra , AnaptysBio Inc, Kardigan, Aes Corp, GE Vernova , Biomarin Pharmaceutical and more - Smartkarma
ANAB (NASDAQ: ANAB) affiliate files Form 144 to sell 20,000 shares - Stock Titan
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ANAB (NASDAQ: ANAB) affiliate files Form 144 listing multiple share dispositions - Stock Titan
Q2 Earnings Forecast for AnaptysBio Issued By HC Wainwright - MarketBeat
AnaptysBio, Inc. Stock 12‑Month Price Target Raised to $81.5, Implies 50% Upside - TradingView
Morgan Stanley (ANAB) plans 35,000-share sale; multiple insider dispositions listed - Stock Titan
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
ANAB Assumed by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating By Investing.com - Investing.com Nigeria
H.C. Wainwright initiates AnaptysBio stock coverage with buy rating - Investing.com
H.C. Wainwright Initiates AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $95 - Moomoo
AnaptysBio Coverage Assumed by HC Wainwright & Co. at Buy - Moomoo
AnaptysBio, Inc. $ANAB Shares Acquired by BNP Paribas Financial Markets - MarketBeat
ANAB (ANAB) insider files Form 144 to sell 20,000 shares via option exercise - Stock Titan
ANAB (NASDAQ: ANAB) Form 144 shows Dennis Mulroy selling multiple lots - Stock Titan
ANAB (NASDAQ: ANAB) director reports multiple stock-option sales, dates listed - Stock Titan
ANAB insider resale filed: 20,000 shares via option (ANAB) - Stock Titan
AnaptysBio earnings up next: First report as royalty company - Investing.com
AnaptysBio (NASDAQ:ANAB) Lowered to "Hold" Rating by Zacks Research - MarketBeat
20,000 ANAB Shares Registered; Dennis Mulroy Sold Multiple Lots (ANAB) - Stock Titan
ANAB (NASDAQ) affiliate to sell 20,000 shares via cash option exercise - Stock Titan
Affiliate of ANAB (NASDAQ: ANAB) to sell 7,691 shares after option exercise - Stock Titan
AnaptysBio posts Form 8937 on tax treatment of First Tracks spin-off dividend - TradingView
Spin-off dividend tax info posted by AnaptysBio (NASDAQ: ANAB) - Stock Titan
ANAB proposes sale of 15,000 shares (NASDAQ: ANAB) - Stock Titan
ANABAnaptysBio Inc Stock Price and Quote - Finviz
AnaptysBio, Inc.Common Stock (NQ: ANAB - FinancialContent
ANAB (NASDAQ: ANAB) director reports May sales and 10,264‑share exercise - Stock Titan
Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR) - The Globe and Mail
AnaptysBio (ANAB) may find a bottom soon, here's why you should buy the stock now - MSN
Dennis Mulroy files Form 144 to sell shares (ANAB) - Stock Titan
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating - Moomoo
ANAB (ANAB) Form 144: Insider-linked 10,000-share sale disclosed - Stock Titan
AnaptysBio Inc. (ANAB) Q1 2026 Earnings: Significant EPS Miss Amid Clinical ProgressSpecial Dividend Alert - newsline.com
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $70 - Moomoo
Affiliate sale notice: ANAB (NASDAQ: ANAB) plans 10,000-share sale - Stock Titan
AnaptysBio Inc (ANAB) Stock Price, Quote, News & History - Benzinga
Wall Street analysts see a 38.75% upside in AnaptysBio (ANAB): Can the stock really move this high? - MSN
AnaptysBio (NASDAQ: ANAB) moves fiscal year-end to June 30, 2026 - Stock Titan
AnaptysBio, Inc. Approves Change in Fiscal Year-End from December 31 to June 30 - marketscreener.com
Is AnaptysBio (ANAB) outperforming other medical stocks this year? - MSN
Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year? - Yahoo Finance UK
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
TRAXV SEC FilingsFirst Tracks Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
ANAB Technical Analysis | Trend, Signals & Chart Patterns | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Dennis Mulroy (ANAB) files to sell 10,000 shares via option exercise - Stock Titan
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High? - Yahoo Finance
AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):